TW200526622A - Novel piperidine-substituted indoles- or heteroderivatives thereof - Google Patents
Novel piperidine-substituted indoles- or heteroderivatives thereof Download PDFInfo
- Publication number
- TW200526622A TW200526622A TW093135011A TW93135011A TW200526622A TW 200526622 A TW200526622 A TW 200526622A TW 093135011 A TW093135011 A TW 093135011A TW 93135011 A TW93135011 A TW 93135011A TW 200526622 A TW200526622 A TW 200526622A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- formula
- alkyl
- doc
- het
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 105
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 claims abstract 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 claims abstract 2
- -1 formazan yellow Acid salt Chemical class 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 101100533890 Hypocrea jecorina (strain QM6a) sor3 gene Proteins 0.000 claims description 5
- 101100533874 Hypocrea jecorina (strain QM6a) sor5 gene Proteins 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 101100295738 Gallus gallus COR3 gene Proteins 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- CZHYAAVLICZNRV-UHFFFAOYSA-N (4-bromophenyl)methanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=C(Br)C=C1 CZHYAAVLICZNRV-UHFFFAOYSA-N 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 101150047265 COR2 gene Proteins 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- 102100035353 Cyclin-dependent kinase 2-associated protein 1 Human genes 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 241000736199 Paeonia Species 0.000 claims 1
- 235000006484 Paeonia officinalis Nutrition 0.000 claims 1
- 101100467189 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) QCR2 gene Proteins 0.000 claims 1
- 150000001924 cycloalkanes Chemical class 0.000 claims 1
- 210000004268 dentin Anatomy 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 claims 1
- 101150003374 sor2 gene Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 239000000556 agonist Substances 0.000 abstract description 3
- 239000005557 antagonist Substances 0.000 abstract description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 45
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 235000002639 sodium chloride Nutrition 0.000 description 22
- 102000009410 Chemokine receptor Human genes 0.000 description 20
- 108050000299 Chemokine receptor Proteins 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 206010020751 Hypersensitivity Diseases 0.000 description 9
- 208000026935 allergic disease Diseases 0.000 description 9
- 230000000172 allergic effect Effects 0.000 description 9
- 208000010668 atopic eczema Diseases 0.000 description 9
- 230000003399 chemotactic effect Effects 0.000 description 9
- 229940088597 hormone Drugs 0.000 description 9
- 239000005556 hormone Substances 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 210000003979 eosinophil Anatomy 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 208000006673 asthma Diseases 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 7
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 6
- 108010055166 Chemokine CCL5 Proteins 0.000 description 6
- 102000019034 Chemokines Human genes 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 description 6
- 201000004681 Psoriasis Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 201000009564 autosomal recessive limb-girdle muscular dystrophy type 2A Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 5
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 5
- 108091006027 G proteins Proteins 0.000 description 5
- 102000030782 GTP binding Human genes 0.000 description 5
- 108091000058 GTP-Binding Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 230000035605 chemotaxis Effects 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000002932 luster Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 229940098465 tincture Drugs 0.000 description 5
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 4
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 4
- 102000001902 CC Chemokines Human genes 0.000 description 4
- 108010040471 CC Chemokines Proteins 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 201000001981 dermatomyositis Diseases 0.000 description 3
- 230000002327 eosinophilic effect Effects 0.000 description 3
- 201000009580 eosinophilic pneumonia Diseases 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000003182 parenteral nutrition solution Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 102100031174 C-C chemokine receptor type 10 Human genes 0.000 description 2
- 101710109563 C-C chemokine receptor type 10 Proteins 0.000 description 2
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 2
- 101710149872 C-C chemokine receptor type 8 Proteins 0.000 description 2
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- 108050006947 CXC Chemokine Proteins 0.000 description 2
- 102000019388 CXC chemokine Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010011686 Cutaneous vasculitis Diseases 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 206010013700 Drug hypersensitivity Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 101000978374 Mus musculus C-C motif chemokine 12 Proteins 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 206010047124 Vasculitis necrotising Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 description 2
- 208000028004 allergic respiratory disease Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 150000002475 indoles Chemical group 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 230000002956 necrotizing effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 201000004335 respiratory allergy Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 208000004441 taeniasis Diseases 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 208000003982 trichinellosis Diseases 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- CMGXWQYKWOSQHO-UHFFFAOYSA-N 1,2,2,3,3,4-hexachloro-4H-pyridine Chemical class ClC1C(C(N(C=C1)Cl)(Cl)Cl)(Cl)Cl CMGXWQYKWOSQHO-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ZXVNARIZQDCUIQ-UHFFFAOYSA-N 1-(1-benzylpiperidin-4-yl)-2-ethyl-5-fluoroindole Chemical compound CCC1=CC2=CC(F)=CC=C2N1C(CC1)CCN1CC1=CC=CC=C1 ZXVNARIZQDCUIQ-UHFFFAOYSA-N 0.000 description 1
- GCHCRHBAGFHFMV-UHFFFAOYSA-N 1-benzyl-n-(4-fluorophenyl)piperidin-4-amine Chemical compound C1=CC(F)=CC=C1NC1CCN(CC=2C=CC=CC=2)CC1 GCHCRHBAGFHFMV-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FADJIMDKDQYNCG-UHFFFAOYSA-N 1h-azet-2-one Chemical group O=C1NC=C1 FADJIMDKDQYNCG-UHFFFAOYSA-N 0.000 description 1
- HIYWOHBEPVGIQN-UHFFFAOYSA-N 1h-benzo[g]indole Chemical compound C1=CC=CC2=C(NC=C3)C3=CC=C21 HIYWOHBEPVGIQN-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical class CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- XDZMPRGFOOFSBL-UHFFFAOYSA-N 2-ethoxybenzoic acid Chemical class CCOC1=CC=CC=C1C(O)=O XDZMPRGFOOFSBL-UHFFFAOYSA-N 0.000 description 1
- XJALAKQSCCJQSK-UHFFFAOYSA-N 2-ethyl-5-fluoro-1h-indole Chemical compound FC1=CC=C2NC(CC)=CC2=C1 XJALAKQSCCJQSK-UHFFFAOYSA-N 0.000 description 1
- UBDFRZKWMQOFLE-UHFFFAOYSA-N 2-ethyl-6-fluoro-3-piperidin-4-yl-1h-indole Chemical compound CCC=1NC2=CC(F)=CC=C2C=1C1CCNCC1 UBDFRZKWMQOFLE-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- HNQZRUDJRPSFAU-UHFFFAOYSA-N 2-piperidin-1-yl-1h-indole Chemical class C1CCCCN1C1=CC2=CC=CC=C2N1 HNQZRUDJRPSFAU-UHFFFAOYSA-N 0.000 description 1
- VQHLASZKZRDUEE-UHFFFAOYSA-N 2-propylbenzenecarbothioic s-acid Chemical compound CCCC1=CC=CC=C1C(O)=S VQHLASZKZRDUEE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 1
- HTPXFGUCAUTOEL-UHFFFAOYSA-N 9h-fluorene-1-carboxylic acid Chemical compound C1C2=CC=CC=C2C2=C1C(C(=O)O)=CC=C2 HTPXFGUCAUTOEL-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001147672 Ancylostoma caninum Species 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- 241000244023 Anisakis Species 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 102100036302 C-C chemokine receptor type 6 Human genes 0.000 description 1
- 101710149871 C-C chemokine receptor type 6 Proteins 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 108010039171 CC cytokine receptor-4 Proteins 0.000 description 1
- 102000004499 CCR3 Receptors Human genes 0.000 description 1
- 108010017316 CCR3 Receptors Proteins 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010009344 Clonorchiasis Diseases 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 201000000077 Cysticercosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010014096 Echinococciasis Diseases 0.000 description 1
- 208000009366 Echinococcosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010053776 Eosinophilic cellulitis Diseases 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000006353 Filariasis Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102000013818 Fractalkine Human genes 0.000 description 1
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000006968 Helminthiasis Diseases 0.000 description 1
- 101000946926 Homo sapiens C-C chemokine receptor type 5 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 201000009324 Loeffler syndrome Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical group [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 241001247287 Pentalinon luteum Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 206010042254 Strongyloidiasis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000242541 Trematoda Species 0.000 description 1
- 241000869417 Trematodes Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010044608 Trichiniasis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical class OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000004222 fluoren-1-yl group Chemical group [H]C1=C([H])C2=C(C([H])=C1[H])C([H])([H])C1=C(*)C([H])=C([H])C([H])=C21 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000013397 idiopathic acute eosinophilic pneumonia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- CPRRHERYRRXBRZ-SRVKXCTJSA-N methyl n-[(2s)-1-[[(2s)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O CPRRHERYRRXBRZ-SRVKXCTJSA-N 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical class OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 239000002897 polymer film coating Substances 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical compound CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 229940076376 protein agonist Drugs 0.000 description 1
- 229940076372 protein antagonist Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000012748 slip agent Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 125000004354 sulfur functional group Chemical group 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 201000007588 trichinosis Diseases 0.000 description 1
- 208000009920 trichuriasis Diseases 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Description
200526622 九、發明說明: 【發明所屬之技術領域】 本發明一般而言係關於經六氫吡啶取代之吲哚或其雜環 衍生及其作為趨化激素(chemokines)受體或其調節劑之用 途、含有該化合物之醫藥組合物及使用該化合物作為治療 及預防發炎性疾病例如氣喘和過敏性疾病,以及自體免卢 病理學例如類風濕關節炎和動脈硬化藥劑之方法。 【先前技術】 趨化激素為趨化性細胞激素,分子量6-1 5 kDa係由各種 不同細胞所釋放用以吸引或活化細胞,其中之細胞類型為 (但不限於),巨噬細胞、T及B淋巴細胞、嗜伊紅血球 (eosinophils)、嗜驗白血球(basophil)及中性細胞 (neutrophil)(參見 Luster,New Eng. J Med·,338, 436-445(1998)及 R〇llins,Blood,90, 909-928(1997))。 有兩種主要的趨化激素,cxc及cc,係依照在胺基酸序 列中前兩個半胱胺酸是否被一單一的胺基酸(CXC)分隔開 或是相鄰(CC)。CXC趨化激素例如介白素-8(IL-8)、中性 細胞活化蛋白-2(NAP2)及黑素瘤生長刺激活性蛋白 (MGSA),主要為中性細胞及T淋巴細胞之趨化激素,而 CC趨化激素例如RANTES、MIP-la、MIP-1(3,單核細胞 趨化蛋白(MCP-1、MCP-2、MCP-3、MCP-4及 MCP-5)及嗜 酸性粒細胞趨化激素(eotaxin)(-l,-2,及-3),於各種細胞 類型中,為巨噬細胞、T淋巴細胞、嗜伊紅血球 (eosinophils)、樹突細胞及嗜驗白血球(basophil)之趨化激 97000.doc 200526622 素。另外亦存在之趨化激素有,淋巴細胞趨化激素-1、淋 巴細胞趨化激素-2(兩者皆為c趨化激素)及膜結合趨化激素 (fractalkine)(CXXXC趨化激素)其並不在主要的趨化激素 亞族中。 與特定細胞表面受體結合之趨化激素係屬於G-蛋白偶合 七跨膜結構域蛋白(G-protein-coupled seventransmembrane-domain proteins)之家族(參見 Horuk,Trends Pharm. Sci·, 15,159-165(1994)),其係稱為「趨化激素受體」。在與其 同源配體結合時,趨化激素受體將經由相關的三聚體G蛋 白轉換胞内訊息,導致各種反應(但不限於),如胞内鈣離 子濃度快速增加、細胞形狀改變、細胞的黏附分子表現增 加、細胞去顆粒作用及細胞遷移變快。至少有十種可結合 或對CC趨化激素有反應的人類趨化激素受體具有下列特 性模式:〇€111(或’’(^11-1’’或”(3(:-0^11-1”)[1^1?-1&,以〇?-3, MCP-4,RANTES](Ben_Barruch 等人,Cell,72,415-425 (1993),Luster, New Eng. J. Med., 338,436-445(1998)); CCR-2A 及 CCR-2B(或,,CKR-2A,,/”CKR-2B1,’CC-CKR- 2An/f,CC-CKR-2Bn)[MCP-l? MCP25 MCP-3, MCP-4, MCP-5](Charo等人,Proc·Natl·Acad·Sci.USA,91,2752-2756(1994),Luster,New Eng· J. Med·,338,436-445 (1998)) ; CCR-3(或,,CKR_3,’*nCC-CKR-3,,)[嗜酸性粒細胞 趨化激素-1,嗜酸性粒細胞趨化激素-2,RANTES,MCP-3, MCP-4](Combadiere 等人,[81〇1.0^111.,270,16491-16494(1995),Luster,New Eng. J· Med·,338, 436-445 97000.doc 200526622 (1998)) ; CCR-4(或”CKR-4,,或 ”CC-CKR-4”)[TARC,MIP-la, RANTES,MCP-l](Power等人,厂3沁1.〇^111.,270,19495-19500(1995),Luster,New Eng. J. Med·,338,436-445 (1998)); CCR-5(或’’CKR-5”或,’CCCKR-5’f)[MIP-la,RANTES, MIP-lp](Sanson等人,Biochemistry,35,3362-3367 (1996)); CCR-6(或,,CKR-6▼,或 f,CC-CKR-6,,)[LARC](Baba 等人,J· Biol· Chem·,272,14893-14898(1997)); CCR-7(或1’CKR-7” 或,fCC-CKR-7,,)[ELC](Yoshie 等人,J. Leukoc. Biol. 62, 634-644(1997)) ; CCR-8(^nCKR-8’1nCC-CKR-8,,)[l-309, TARC,MIP_lp](Napolitano等人,J. Immunol., 157, 2759-2763(1996),Bernardini 等人,Eur· J. Immunol·,28,582- 588(1998));及 CCR-10(或 nCKR-l〇” 或 ’’CC-CKR-10”) [MCP-1,MCP-3](Bonini等人,DNA and Cell Biol·,16, 1249-1256(1997))。 除了哺乳動物趨化激素受體外,哺乳動物巨細胞病毒、 疱疹病毒及痘病毒已顯示,於受感染的細胞中,可表現具 有與趨化激素受體結合特性之蛋白(參見Wells& SchwartZ, Curr. Opin· Biotech·,8,741刀48(1997))。人類 CC趨化激 素,例如RANTES及MCP-3可造成鈣經由14些病毒所編碼 受體而快速移動。受體表現可容許藉由破壞正常免疫系統 監督及對感染之反應來感染。此外,人類趨化激素受體, 例如 CXCR-4、CCR-2、CCR-3、CCR_5 及 CCR-8 可作為哺 乳動物細胞被微生物感染與例如人類免疫缺乏病毒(HIV) 之共受體。 97000.doc 200526622 趨化激素文體已顯示為一重要的發炎性、感染性及免疫 調節性症狀和疾病之介質,包括氣喘及過敏性疾病以及自 體免疫病理學例如類風濕關節炎及動脈硬化。例如,趨化 激素受體CCR-3在吸引嗜伊紅血球至過敏發炎位置及隨後 活化14些細胞上扮演一個樞軸的角色。CCR_3之趨化激素 配體導致胞内鈣濃度快速增加、細胞去顆粒作用及嗜伊紅 血球遷移變快。因此,可調節趨化激素受體之藥劑應可有 效用於該等症狀和疾病。此外,可調節趨化激素受體之藥 劑應可有效用於感染性疾病例如藉由阻斷HIV所引起之 CCR-3表現細胞感染,或用於預防由病毒(例如巨細胞病 毒)引起的免疫細胞反應之操作。 -US 5,521,197揭不以經六氣^比σ定取代之叫丨σ朵作為$ ητ 激動劑。 -國際專利申請案WO 98006402揭示了這些化合物用於治 療感冒或過敏性鼻炎之用途。 -W Ο 9 8 01 1 8 9 5揭不了這些化合物用於治療偏頭痛。 -WO 2001043740揭示了類似的化合物作為5-ΗΤ調節劑。 -WO 2002008223揭示了與經胜肽取代之芳基環相關之經 六氫吡啶取代之吲哚作為D4調節劑,但同時對5_ΗΤμ < 5-11丁2(:受體亦具有部分效用。 -WO 99037304揭示了經取代之經六氫吡啶及六氯吼呼衍 生物作為ΧΑ因子之抑制劑。 -WO 2000075 130揭示吲哚基六氫吡啶衍生物作為抗組織 胺劑及抗過敏劑,其包含治療慢性氣喘。 97000.doc 200526622 潛藏於本發明下的問題為提供新穎的ccr_3調節劑。令 人意外的發現某些經六氫吼啶取代之吲哚非常適合作為 C C R - 3調節劑。 【發明内容】 口此本發明之目的之一係提供式1之經六氫吡啶取代 之吲哚或其雜環衍生物: ^~(R6)m
r,Y、a,nW 其中 Rl、Λ 、A、B、D-E、X-W-V、Y、i、j及 m之; 義如下。 本啦月另個目的係提供CCR_3激動劑或拮抗劑,或, 醫樂上可接受之_逮首 類’更特而言之係提供包含一醫藥上, 接受之載劑及治瘆右 一 摩有效置之至少一種本發明化合物或其〗
藥上可接受之鹽類較 、之面条組合物。該等目的及其他目的; 於下列詳細說明中审 凡月〒更加彰顯出。 【實施方式】 本發明係關於式(I)化合物 R1
97000.doc -10· 1 200526622 其中 Rl 為务基het或其增環部分(anneiated Species), 其中het為一雜環而增環部分係包括芳基_he卜、 het-芳基-或het-he卜增環,每一個該芳基或可經 一、二或三個R2取代; R2 各自分別為烷基、C3|環烷基、Ci 6- ^烷 基、Cw芳烷基、鹵素、CN、COOR3、 COR3、CONR3R4、NR3R4、NR3S02R4、OR3、 N02、SR3、SOR3、S02R3 或 S02NR3R4 ; R3 為H ’ Cw烷基、c3|環烷基或(c3 8_環烷 基Xw-烷基; R4 為H ’ cle6-烷基、c3_8-環烷基或(c3_8-環烷 基)-Cn燒基或 R3 及 R4 與居間的氮原子或n-so2-基團共同形成一個可 視需要經取代之含有3至8個成員的氮雜環 R5 為c^-烷基、Cl_6_烷氧基、Cl6_醯氧基、 Ci-6-务燒基、C3.6-環烧基、(C3_6-環烧 基)-Cn燒基、鹵烧基、Ci_6 -硫烧基、鹵 素、N02、CN ; R6 各自分別為Ci_6-烧基、Ci_6-烧氧基、Ci_6_醯氧 基、ci-6-芳烷基、C3_6-環烷基、CU6__烷基、 Cu-硫烷基、鹵素、OR3、SR3、CN、n〇2、 COOR3、c〇R3、c〇NR3R4、nr3r4、 NR3COR4、NR3S02R4、SOR3、S02R3、 97000.doc -11 - 200526622 A so2nr3r4、芳基或het; 為(C3·6^燒基)伸烧基、直鍵或支鍵 B C2-8·伸烧基、視需要經鹵素或OH取代; 為芳基或het ; D-E 為 CH-CH2-或 c=CH- X-W-V 為 N-C=CR7或 c=C-NR7 ; R7 為Η或CN6-燒基; Y 為 CF2、NR4、〇、s(〇)n ; i、j 各自分別為0、1或2 ; η 為〇、1或2 ; m 為 〇、1、2、3或 4 ; 及其醫藥上可接受之鹽類。 本文所描述之化合物可具有不對稱中心。含有一不對稱 經取代原子 之本發明化合物,可分離成光學活性及外消旋 的形式。本項技•中已知如何製備光學活化形式,例如將 外消旋形式分解或由光學活性的起始物質來合成。許多稀 Γ幾何異構物及其類似物可存在於本文所描述的化合物 ^且所有該等安定的異構物皆涵蓋在本發明中。本發明 化口物之順式和反式幾何 m 稱物已有榣述,且可分離為昱 構物之混合物或分開的異 的立體化學或異構物形式 "曰出特疋 斜旁π L 則所有的結構係指對掌、兆 對㈣、外消旋形式和所有的幾何異構物之社構 非 所用的術語及定義 之、、力構。 在解釋揭示文及内容時, 對本文中未特別定義之術語應 97000.doc 200526622 ’、白本項技藝者所賦予的意義。然而,如用於本說明 曰 *非特別^出其反面的意義,否則下列術語具有其 所指之意義’而下列為其所附之規則。 在女下疋義之基團、基或部分t ’碳原子數通常係指前 々土團例如c]_6烷基係指一個具有^至6個碳原子之烷 基基團。-般而言’含有兩個或多個亞基之基團,最後命 名的基ϋ係為基ϋ連接點,例如,「硫烧基」係指―式勝 炫基-之單價基。除非下列另有指明,否則術語之控制及 習用安定之原子價的習用定義係指及表示所有化學式及基 一般而言’除非在化合物或結構中有特別指出其特定的 立體化學或異構物形式,否則化學結構或化合物之所有的 互變異構物形式及異構物形式及遇合物,無論個別的幾何 異構物或光學異構物或外消旋或非外消旋異構物之混合 物’皆為所欲的。 本文所用的術語「經取代」係、指在指定原子上任何一個 或多個氣,被選自指定的基團取代,但是不能超過所指定 的原子之正常價’且該取代作用係產生—安定的化合物。 本文所用的「醫藥上可接受」—辭係指該等化合物、物 質、組合物及/或劑型,在良好的醫學判斷範圍内,適人 用於與人類及動物的㈣接觸,沒有過量的毒性、刺激 性、過敏反應或其他問題或併發症,評估具有合理的利益 /風險比例。 本文所用「醫藥上可接受之鹽類」係指所揭示化合物之 97000.doc -13- 200526622 衍生物,其中該母化合物係以其酸或鹼鹽修飾過。醫藥上 、 可接受之鹽類的實例包括(但不限於)鹼性殘基之無機或有 機酸鹽例如胺;酸性殘基之鹼鹽或有機鹽類,例如羧酸, • 及其類似物。醫藥上可接受之鹽類包括,例如由無毒無機 或有機酸所形成的母化合物之習用無毒鹽類或第四銨鹽。 例如該等習用之無毒鹽類包括由無機酸例如鹽酸、氫溴 酸、硫酸、磺胺酸、硫酸、硝酸及其類似物所衍生的鹽 類;及由有機酸,例如乙酸、丙酸、琥珀酸、甘醇酸、硬 脂酸、乳酸、蘋果酸、酒石酸、檸檬酸、抗壞血酸、帕莫 酸、馬來酸、羥基馬來酸、苯乙酸、麵胺酸、苯甲酸、水 揚酸、對胺基笨磺酸、2-乙醯氧基苯甲酸、延胡索酸、甲 苯磺酸、甲磺酸、乙二磺酸、草酸、異硫代硫酸 (isothionic)的鹽類。 本發明醫藥上可接受之鹽類可由含有—鹼性或酸性基團 之母化合物利用習用的方法來製備。一般而言,該等鹽類 可藉由將游離酸或鹼形式之該等化合物與化學劑量之適合 的酸或鹼於水或有機溶劑或兩者的混合物中反應;通常非 水性的媒劑如乙键、乙酸乙醋、乙醇、異丙醇或乙猜為較 么。適合鹽類之列表可參見Remingto中,當該前藥投予哺 乳動物體時,其在活體中會釋出一種本發明化合物之活性 原藥。本發明之前藥可藉由修飾存在於化合物之官能基來 ’ t備,而該方式可在制式的操作中或在活體中,將該修飾 : 解開形成母化合物。前藥包括本發明化合物,#㈣基、 胺基或疏基(sulfhydryl)可鍵結至任何基團上,當本發明前 97000.doc -14- 200526622 藥投予一哺乳動物體時,其將斷裂分別形成游離的羥基、 游離的胺基或游離的巯基。前藥之實例包括(但不限於)本 發明化合物之醇及胺官能基團之乙酸鹽、甲酸鹽及苯甲酸 鹽衍生物。 本文所用的術語「芳基」單獨或與其他取代基組合時, 係指一含有碳原子之芳香系單環系統或芳香系多環系統。 例如,芳基係包括一苯基或萘基環系,其中芳基一般係指 一芳香系統,例如苯基。 本文所用的術語「het」單獨或與其他取代基組合時, 係指一單價的取代基,藉由從含有碳原子及一、二、三或 四個選自t、氧及硫之雜環原子之五'六或七元的飽和或 不飽和(包括芳香系)雜環中,將氯移除所衍生的。適合雜 環之實例包括:四氫t南…塞吩、二氮呼、異十坐、六氫 σ比畊、嗎琳、六氫。比畊或
雖然本文所用的術語「雜芳基」係涵蓋在術語「^ 之下 指-不飽和雜環,而其雙鍵形成 方曰糸31合的雜芳香系統之實例包括料…密咬。 ^8; Ν^; Ο. 〇. Cl ^ ;或 本文所用的術語 芳基或het之增環部分」單獨或與其他 97000.doc -15 - 200526622 ,代基組合時’其中增環部分係代表―芳基如⑷、 芳基(b)或-het_het(e),增環作用係指—單價取代基,藉 由將一個氫離子從下列各基中移除所衍生的 a)將氫從_含有碳原子之芳香單環系統或芳香多環系統中 移除,該芳香單環系統或芳香多環系統係與含有碳原子 及、—、二或四個選自氮、氧及硫之雜環原子之五、 b)將氫從一含有碳原子及一 六或七元的飽和或不飽和(包括芳香系)雜環連結,或 二、三或四個選自氮、氧及 硫之雜環原子之五、六或七元的飽和或不飽和(包括芳 香系)雜環中移除,其中該雜環係與一含有碳原子之芳 香單環系統或芳香多環系統連結,或 c)將氫從一含有碳原子及一、二、三或四個選自氮、氧及 石瓜之雜%原子之五、六或七元的飽和或不飽和(包括芳 香系)雜環中移除,其中該雜環係與含有碳原子及一、 一、二或四個選自氮、氧及硫之雜環原子之五、六或七 元的飽和或不飽和(包括芳香系)雜環相連結。 適合的芳基或het連環部分之實例包括:喹啉、丨_吲哚 基、3-吲哚基、5-吲哚基、6-吲哚基、苯并咪唑 (benzimidazyl)或嘌呤。 本文所用的術語「鹵素」係指選自氟、氣、溴或碘之鹵 素取代基。 本文所用的術語「烷基」單獨或與其他取代基組 合時係指含有一至六個碳原子之環狀、直鏈或支鏈之烷基 取代基,其包括甲基、乙基、丙基、丁基、己基、1-甲基 97000.doc -16- 200526622 乙基、1-甲基丙基、2-甲基丙基或丨,“二甲基乙基。 本文所用的術語「-C3_8-環烷基」單獨或與其他取代基 組合時係指一含有三至六個碳原子之環烷基取代基,其包 括環丙基、環丁基、環戊基或環己基。 本文所用的術語「鹵烷基」單獨或與其他取代基 組合時係指含至高六個碳原子之環狀、直鏈或支鏈之烷基 取代基,該碳原子具有一或多個選自溴、氣、氟或碘之_ 素取代氫原子。因此,「C2·6-鹵烷基」除了鏈上含有二至 六個碳原子外,亦具有相同之定義。較佳的,Ci-6-鹵烷基 係代表c^-氟烷基,例如三氟甲基、2,2,2•三氟乙基或全 氟乙基。 本文所用的術語「-Cn烧氧基」單獨或與其他取代基 組合時係指取代基CN6_烷基其中烷基係如上述定義含 有至高六個碳原子。烷氧基包括甲氧基、乙氧基、丙氧 基1甲基乙氧基、丁氧基、1-二甲基乙氧基。最後一個 取代基一般係稱為第三丁氧基。 本文所用的術語「-CN6-醯氧基」單獨或與其他取代基 組合時係指取代基烷基-(c〇)〇-,其中烷基係如上述 定義含有至高六個碳原子。醯氧基包括MeCOO-、 EtCOO·、正 prc〇〇_、異 prC00_、正 BuCOO-、第二 BuCOO-或第三BuC〇〇… 本文所用的術語「-CN6-芳烷基」單獨或與其他取代基 組合日卞係指取代基-芳基_ 1 -6-烷基-其中烷基係如上述定義 含有至高六個碳原子。芳烷基包括苯甲基、苯基乙基、苯 97000.doc -17- 200526622 基丙基、1-苯基-1-甲基乙基、苯基丁基或苯基二甲 基乙氧基。 本文所用的術語「-Cii硫烧基」單獨或與其他取代基 組合時係指環狀、直鏈或支鏈烷基取代基,其含有至高六 個碳原子及一硫基團(HS)作為取代基。硫烷基基團之實例 有硫丙基,例如HS_CH2CH2CH2-。 本文所用的術語「-C2_8_伸烧基」係指藉由將一個氩原 子從每個含有二至八個碳原子之飽和直鏈或支鏈脂肪係烴 基末端移除,所衍生的二價烷基取代基,其包括例如 CH2CH2C(CH3)2CH2CH2-。因此,「-Cy 伸烷基」除了鏈 上含有一至三個碳原子外,亦具有相同之定義。 較佳實施例 幸父佳的為式1化合物,其中Y為8或s=〇及Ri、R5、R6、 A、B、D-E、X-W-V、i、如上述之定義。特佳的為式 la或lb之化合物, R1
1a
其中Rl、R5、R6、A、B、D-E、X-W-V及m如上述之定 亦較佳的為式1、la或lb之化合物,其中: 為 芳基或het,兩者皆可視需要經一、二或三個r2 取代及 97000.doc -18· 200526622 8為 笨基。 R1為 B為 亦李乂 ^的為式1、la或lb之化合物,其中: 笨基,視需要可經一、二或三個R2取代及 笨基。 亦車又仏的為式1、la或lb之化合物,其中·· 8為 笨基及 D_E為 ch-ch2-。 亦車乂佳的為式1、la或lb之化合物,其中: R1為 » … 苯基,視需要可經一、二或三個R2取代及 8為 笨基及 D — E為 CH-CH2-。 亦車父佳的為式1、la或lb之化合物,其中·· R1為 苯基,視需要可經一、二或三個R2取代及 8為 苯基及 D_E 為 CH-CH2-及 A為 CH2-CH2-CH: 亦較佳的為式1、la或lb之化合物,其中: 為 笨基,視需要可經一、二或三個R2取代及 8為 苯基及 D-E 為 CH_CH2-及 A為 C(CH3)2-CH2-CH2- 亦較佳的為式1、la或lb之化合物,其中: R為 苯基,視需要可經一、二或三個R2取代及 B為 苯基及 97000.doc -19- 200526622 D-E為 ch_ch2-及 一八一 CH2一 CHr /-Ν A為 c 一c h2 h2 0 亦較佳的為式1、la或lb之化合物 ,其中: R1為 苯基,視需要可經一、二或三個R2取代及 B為 求基及 D-E為 CH-CH2-及 Ρ —ρ A為 h2 h2 2 及 R7為 Η 〇 亦車乂仏的為式1、1 a或1 b之化合物 ,其中: R1為 笨基,視需要可經一、二 或三個R2取代及 B為 笨基及 D - E為 ch-ch2-及 :C、-CH2-CHr p^r\ c A為 ^ c h2 h2 及 R7為 Nl e 〇 亦車乂仏的為式1、la或lb之化合物 ,其中: R1為 笨基,視需要可經一、二 或三個R2取代及 B為 笨基及 D-E為 C==CH-。 亦較佳的為式1、la或11}之化合物 ,其中: R1為 笨基,視需要可經一、二 或三個R2取代及 B為 笨基及 97000.doc -20- 200526622 D-E 為 c = CH-及 A為 CH2-CH2-CH2-。 亦較佳的為式1、la或lb之化合物,其中: &為 笨基,視需要可經一、二或三個R2取代及 笨基及 D-E 為 OCH-及 A為 C(CH3)2_CH2-CH2-。 R1為 B為 亦較佳的為式1、la或lb之化合物,其中: 笨基,視需要可經一、二或三個R2取代及 本基及 C==:CH-及 'cfCH-CH2-C-C Ha Η, D-E為 A為 土的為式1、la或lb之化合物,其中: R1為 ^ 本基,視需要可經一 B為 〜 本基及 D-E 為 Γ1 ρ 及 或三個R2取代及 A為 R7為 亦較佳 Ri為 B為 D-E為 BCHfCH2 及 Η 勺為式1、la或lb之化合物,其中: 笨基,視 需要可經一、二或三個R2取代及 笨基及 及 97000.doc -21 - 200526622 A為 'crCHfCHf c—c H2 h2 及 R 為 1VI e 〇 亦較佳的為式t、“或几之化合物,其中·· R1為苯基,視需要可經一、二或三個R2取代及
R 各自分別為 COOR3 、 COR3 、 CONR3R4 、 nr3so2r4、SOR3、so2r3或so2nr3r4 ;特別是 COOR3 或 S02R3 ; R3為 烷基;特別是η或甲基; R4為 H4CN6-烷基;特別是η或甲基; 亦較佳的為式1、la或lb之化合物,其中: R1為 笨基,視需要可經一個R2取代及 R2為 COOR3 或 S02R3 ; R3為 Η或甲基; R4為 Η或甲基; 亦車又佳的為式la或lb之化合物,其中: 或 R為〇1 +燒基、c3_6-環烷基或c2_6-ii烷基 為CF3或i素,特別是氟;或 R幸又佳的為鹵素,特別是氟;或 合物 亦較佳的係為製備式之方法,其特徵 物 、式2化
97000.doc 2 -22- 200526622 與式3化合物反應。 其中 R1、R5、R6、A、〇 、 · β、X-W-V、i、j及m如上述之定義而 LG為 —適合的游離基,特別是_素、甲磺酸鹽、三 氣甲基續酸鹽、甲苯磺酸鹽或對溴苯磺酸鹽。 式1或1 a之化合从π & σ奶可使用下列所述之反應或技術來製 備&應係&適合所用的試劑和物質及適合所欲產生改 艾之今d t進行。熱習有機合成技藝者應了解,分子上的 功月b性應與所欲的轉變一致。有時需要判斷修改合成步驟 的順序或選擇一較伟姓—n ^ 罕乜特疋的處理流程,以便可得到所欲的 本1月化口物。,亦應了解在本領域中規劃任何的合成路徑 另一個主要考慮的因素係明智的選擇用於本發明所述之化 合物中反應性功能基團之保護作用的保護基團。描述許多 其他選擇供專業醫師選擇的權威報告為Greene and wuts (Protective Groups In Organic Synthesis, Wiley and Sons, 1991) 〇 本申清之化合物可有效的用於製造供預防及/或治療與 CCR-3-受:體相關疾病之醫藥品。 較佳的係用於製造供預防及/或治療各種發炎性、感染 性及免疫調節症狀或疾病之醫藥品,該症狀或疾病包括氣 喘及過敏性疾病、病理性微生物感染(依定義,包括病 毒)’以及自體免疫病理例如類風濕關節炎及動脈硬化。 97000.doc -23- 200526622 最佳的係用於製造供預防及/或治療例如發炎性或過敏 性疾病和症狀之醫藥品,該症m病包括呼吸過敏疾病 例如氣喘、過敏性肺部疾病、過敏性肺炎、嗜伊紅性蜂窩 組織炎(例如威爾氏(Well,s)徵候群)、嘻伊紅性肺炎(=二 呂弗勒氏(Loeffler,s)肺炎、慢性嗜伊紅性肺炎)、嗜伊紅性 肌膜炎(例如舒爾曼(Shulman’s)徵候群)、遲發性過敏反 應、間質性肺病(ILD)(例如特發性肺纖維化、或與類風濕 關節炎有關之ILD、全身性紅斑狼瘡、僵直性脊椎炎、全 身性硬化症、修格連氏(Sj0gren,s)徵候群或皮肌炎)、全身 性過敏反應或過敏反應、藥物過敏(例如對盤尼西林或頭 孢菌素(cephalosporins)過敏)、因攝入受污染的色胺酸所 引起的嗜伊紅血球增多性肌肉痛徵候群、昆蟲叮咬過敏、 自動免疫性疾病例如類風濕關節炎、乾癬性關節炎、多發 性硬化症、全身性紅斑狼瘡、重症肌無力、青少年糖尿 病、腎小球腎炎、自體免疫性甲狀腺炎、貝氏症、移植排 斥(例如移植)包括異體移植物的排斥或移植物抗宿主病、 性發炎性腸到疾病例如克隆氏症(Cr〇hn,s disease)及潰瘍性 結腸炎、脊椎關節病變、硬皮病、牛皮癬(包括丁細胞所介 導的牛皮癬)及發炎性皮膚病例如皮膚炎、濕疹、異位性 皮膚炎、過敏型接觸性皮膚炎、蓴麻疹、血管炎(例如壞 死性、皮膚性及過敏性血管炎)、嗜伊紅性肌炎、嗜伊紅 性肌膜炎、與皮膚或器官之白血球浸潤有關之癌症。 製備 式2a之氮經取代化合物可由b環之還原性縮合反應,至 97000.doc -24- 200526622 少藉由位於鄰位的一個胺功能基和氫’經一保護的氮雜環 酮功能基取代來製備;
偶合後,經由敷克醯基化作用(Friedel Crafts acylation)以 α-鹵基-乙醯函化物或經取代之a- i基·乙腈化合物取代氫 原子,之後將其水解成α -嗣基化合物,
(Hal係代表C1或Β〇醯基化反應後,於酸的存在下進行環
其中整個製程中R5、R6、Β、i、j及m係如上述之定義,及 PG為一氮保護基,較佳的為苯甲基基團。 式2c或2d之碳經取代之化合物,係藉由在b環之布赫瓦 爾德(Buchwald)條件下的c-c偶合,至少藉由位於鄰位的 一個硝基功能基和鹵素,經一 α-C-原子之酮功能基取代來 製備; 97000.doc -25- 200526622
(Hal係代表Cl或Br)偶合反應後,於還原的條件下進行環 合;
之後,以氮雜環酮功能基,在酸的存在下將新形成的環縮 合,
接著,以化合物2d的情況而言,係將氮雜環上的雙鍵氫化
i j及m係如上述之定 其中整個製程中R5、R6、B、D_E、 義。 式:Lb-d之化合物可藉由將化合物與式3之化合物反應來 製備, 97000.doc -26- 200526622
其中整個製程中R1、R5、R6、A、B、Υ、i、j及m係如上 述之定義,及 LG為 一適合的游離基,特別鹵素、甲磺酸鹽、三氟 曱基磺酸鹽、甲苯磺酸鹽或對溴苯磺酸鹽。 式le或If之N-甲基化部份可藉由將式lc或Id甲基化來製備。
(叭
1e R1
1f 97000.doc -27- 200526622 其中R、R5、R6、A、B、Y、i、係如上述之定義。 A智本項技藝者應了解,本發明在上述教導說明中可能 有午夕的心正或變化。因此凊了解,在所附的專利申請範 圍的範疇内,本發明可以本文特定描述之外的方法來實 行。 實例1 1-(3-溪-丙基硫基心氟-苯 pjas— 於2對-氟-硫酉分(20.8 ml)及1_3-二漠、丙烧(60 ml)之乙腈 (25〇 ml)溶液中分次加入ΚΧ〇3 (55.0 g)並將混合物回流3 小時。將所產生的鹽及溶劑移除並將產物蒸餾。沸點丨12_ 115°C/1 毫巴(mbar)。 實例2 (1-苯甲基_六氫。比啶-4_基)_(4_氟_苯基)-胺 將4-說苯胺(32.7 g)、,苯甲基六氫σ比啶酮(1〇6.〇 g)及乙 酸(106.0 g)之1,2_二氯乙烷(12〇〇溶液置於15。〇以下的 &度中。攪拌溶液並緩慢的加入乙酸(495 〇 g)及硼氫化鈉 (3 1.2 g)之懸浮液。於攪拌2小時並於室溫再攪拌2小時, 真空移除浴劑。於攪拌下加入乙酸乙酯(5〇〇 m〗)及水(70〇 97000.doc -28- 200526622 ml)並以碳酸鈉(ca· 250 g)中和所產生的混合物。將有機相 分離出’以2 M NaHC〇3>谷液(1〇〇 ml)及水(1〇〇 ml)沖洗, 以硫酸鈉硫酸鈉乾燥。移除溶劑及由乙醚/石油醚再結晶 後,得到53.8 g的燈色晶體產物。溶點:90-92°C。 實例3 1-[2-(1-苯甲基-六氫吼啶-4-基胺基)·苯基>2•氣
將(1-苯甲基-六氫吸啶-4-基)-(4-氟-苯基)_胺le2 g)溶於 1 80 ml笨中並以冰浴冷卻。於3〇分鐘内逐滴加入三氣化石朋 (180 m卜1 Μ己烷溶液)。加入2-氣丁腈(18.6 g)及三氣化 紹(24.0 g)並將產生的化合物加熱回流丨5小時。然後將混 合物冷卻’加入180 ml的2N HC1,將混合物再回流。加入 200 ml水及200 ml CHKl2,以幾份的碳酸鈉將生成的混合 物調整至pH=5。進行相分離,以硫酸鈉將有機相乾燥並移 除溶劑。以快速層析法(96:4 CI^ClyMeOH)將所生成的油 狀物純化得到20.7 g之無色油狀物。 !H NMR (300 MHz, CDC13): 1.10 (3H, t)5 1.62-1.79 (3H, m),2.01-2.36 (6H,m),2.80-2.92 (2H,m),3.43-3.57 (1H, m)5 3·59 (2H,s),5.03 (1H,dd),6.75 (1H,dd),7.16-7.22 (1H, m), 7.23-7.42 (4H,m),7·43 (1H,dd),8.92 (1H,br d). 實例4 97000.doc -29- 200526622 1-(1-苯甲基-六氫吡啶-4-基:)-2-乙基-5-氟-ΐΗ-α引嗓
將1-[2-(1-本甲基-六氫σ比σ定-4-基胺基)-苯基]_2-氯_丁-卜 酮(20.7 g)與250 ml二噚烷、27 ml水及2.3 g硼氫化鈉混合 並加熱至120°C。回流12小時後,另外再加入3·3 g的硼氫 化鈉並將混合物再回流16小時。移除溶劑後,加入200 ml 的水並以150 ml CH2CL進行混合物萃取,接著以硫酸納乾 燦並真空濃縮。快速管柱層析法(96:4 cH2Cl2:MeOH)將所 生成的油狀物純化得到11>9 g淡黃色的油狀物。 4 NMR (400 MHz,DMSO): 1.25 (3H,t),1.72 (2H,br d), 2.19 (2H,br t),2.39-2.48 (2H,m),2.79 (2H,q),2.98 (2H, br d),3·59 (2H,s),4.12-4.25 (1H, m),6.19 (1H,s),6.88 (1H,td),7.19 (1H,dd),7.21-7.31 (1H,m),7.31-7.39 (4H, m),7·49_7·52 (1H,m)· 實例5 ^(六氫吡啶-心基丨^-乙基^-氟^札吲哚
97000.doc -30- 200526622 將1-(1-苯甲基-六氫吡啶-4-基)-2-乙基-5-氟-1H-吲哚 (11.9 g)及乙酸(4.1 ml)之曱醇(250 ml)溶液氫化8小時 (50°C/10 13毫巴)。然後將混合物過濾並真空濃縮。加入 CH2C12(250 ml)、NaHC03(100 ml)及水(300 ml)並將混合物 攪拌10分鐘。以CHC13萃取有機層並將其乾燥(MgS〇4)及 真空濃縮。由乙醚/石油醚再結晶後,得到6.4 g純產物 (73%)之無色的結晶。 lH NMR (400 MHZ, DMSO): 1.25 (3H, T), 1.65 (2Η? BR D)? 1.83 (1Η,S),2.22-2.37 (2Η,Μ),2.62 (2Η,TD),2·79 (2Η, Q),3.10 (2H,BR D),4.20-4。31 (1H,M),6.18 (1H,S),6.83 (1H,TD),7.19 (1H,DD),7.59-7.14 (1H,M). 實例6 2-乙基-5-氟氟-苯基硫基)_丙基]_六氫σ比啶-4_ 基}-111-吲哚
將ι-(ι-笨曱基_六氫吡啶_4-基戶2-乙基-5_氟_1]9[•吲哚(2·4 g)、1-(3·溴-丙基硫基)_4-氟·苯(24 g)、乙腈及碳酸鉀之混 合物加熱回流5小時。移除溶劑並以快速管柱層析法(1:1乙 酉欠乙知·石油醚)將所生成的油狀物純化。將含有產物的分 /合/夜之/合劑釋出並以乙醇將產生的油狀物結晶。得到1g 97000.doc -31 - 200526622 (30%)之無色結晶。
Mp: 82-84〇C ; ln NMR p〇〇 MHz5 CDC13): 1.33 (3H? t? J 7.5),1.77-1.87 (4H,m),2.10(2H,td,J12.5,J2.5),2.48-2.66 (4H? m)5 2.75 (2H? q? J 7.5), 2.94-3.08 (4H? m), 4.02-4.15(1H,m),6.20(lH,s),6.83(lH,td,J9.5,J2.5),6.98- 7.04 (2H,m),716 〇H,dd,j 9.5, j 2.5),7.36-7.40 (2H,m), 7_47(lH,dd,j9〇,j4〇) i3CNMR(75MHz,CDCl3): 13·23,21.12,26.95,30.62,33.10,53.88,54.11,57.10, 98·85,1(M·70,105.00,108.12,108.46,112.07,115.98, 116·27,129·3〇,132.22,132.33,144.20,156.05,159.15, 160.21,163.48. 實例7 1-(2-硝基-4-氟_笨基)_丁 酮
於 1-漠-2-硝基-4-氟·苯基(6.2 g)、Pd2dba3(260 mg)、2-二環己基膦·2’-(ν,Ν-二甲基胺基)二苯基(455 mg)、 Κ3Ρ〇4(13·7 g)及4·甲氧基酚(7〇〇 mg)之甲苯(60 ml)溶液中 加入2 -丁嗣(5.6 ml)並於氮氣壓下將反應混合物加熱至 60°C24小時。之後以水及乙酸乙酯(1:1)萃取混合物,並以 2M NaOH及水沖洗。移除溶劑,以快速層析法(9:1環己燒: 乙酸乙酯)將殘餘產物純化得到2.6 g (44%)淡黃結晶之純 97000.doc -32- 200526622 物質。 lH NMR (400 MHz, DMSO): 0.98 (3H? t)5 2.56 (2H5 q)? 4.22 (2H,s),7.51 (1H,dd),7.63 (1H,td),7·98 (1H,dd). 實例8 2 -乙基-6-氟_ 1H-H。朵
將1-(2-硝基-3-氟-苯基)_ 丁 _2-S同(2.5 g)之乙醇(2 5 ml)溶 液加熱至70C。加入Na2S2〇4(l〇.7 g)之水(30 ml)溶液並將 生成的混合物加熱回流1小時。蒸餾將乙醇移除,以乙酸 乙酯萃取殘餘物兩次,然後以水沖洗有機層並乾燥。移除 溶劑,並以快速層析法(9:1環己烷:乙酸乙酯)將殘餘物的 雜質去除。得到1·3 g (67%)白色結晶固體之純產物。 4 麵R (400 MHz,DMS0): h26 (3H,t),2 72 (2H,q),6 12 (1H,s),6.73-6.80 (1H,m),7.02 (1H,br d),7·37 (1H,dd), 10.98 (1H,br s). 實例9 2-乙基-6-氟-3_(1,2,3,6-四氫-α比啶基)-iH-吲哚
F
97000.doc -33- 200526622 於2-乙基-5-氟-1H-吲哚(1.2 g)之乙酸(21 ml)懸浮液於 90°C加入4-六氫处啶酮(3.4 g)及2N磷酸(7 ml)之混合物。 於95°C將反應混合物攪拌4小時,然後加入水(5〇 ml)並讓 反應冷卻至室溫。以濃NaOH溶液將pH調整至11,並以乙 酸乙醋萃取混合物。以水沖洗,置於硫酸鎂上乾燥並真空 濃縮。沖洗產物(乙醚)並以抽氣過濾器乾燥,得到丨.5 g (84%)白色結晶個體之產物。熔點ι94-6^。 實例10 2-乙基-6-氟-3-[l-(4-氟-苯基-硫基-丙基)_1,2,3,6·四氫_口比 唆-4-基]-1H-S| σ朵
將2-乙基-6-敗-3-(1,2,3,6-四氫-口比口定-4-基)-111-口引口朵(1.5 g)、1-(3-漠-丙基硫基)-4-氟-苯(1.7 g)、蛾化|甲(20 mg)和 碳酸鉀(1.1 g)之DMF(10 ml)溶液加熱至95°C1小時。然後 加入乙酸乙酯(80 ml)及水(35 ml)並以乙酸乙酯進一步萃取 有機層。乙水沖洗萃取液,乾燥(MgS04)並真空濃縮。以 快速層析法(100:2 CH2Cl2:MeOH)純化粗產物,並於丙酮 中與適量的稀HC1反應來製備其鹽酸鹽,得到1.7 g(55%)白 色結晶之純產物。熔點135°C。 實例11 97000.doc -34- 200526622 2-乙基-6-氟-3-六氫°比°定_4-基-1H-吲哚
F
於10% Pd/C催化劑(〇·3 g)及甲醇(25 ml)的存在下,將3· (1-苯甲基-1,2,3,6-四氫-°比°定-4_基)-2 -乙基·6 -氟-1Η-, α朵 (1.4 g),氫化1小時(室溫/1013毫巴)。過濾將催化劑移 除,蒸發溶劑並以小量的乙沖洗殘餘物。得到] • z g (85%)純產物。 咕 NMR (400 MHz,DMSO): 1.20 (3H,t),1.52 (2H,br 1.90-2.04 (2H,m),2.59-2.71 (4H,m),2.71-2.83 (in, 3.07 (2H,br d),6.74 (1H,t),6.99 (1H,d),7.52-7.60 ⑽ m)? 10.72 (1H? br s). 實例12 2-乙基-6-氟-3-{1-[3-(4-氟-苯基硫基)_丙基l·六氫呀^定、 基}-111-。引哚
F
將2-乙基-6-氟-3-六氫吡啶-4-基-1H-吲哚(0_9 g)、κ(3 97000.doc -35- 200526622 漠-丙基硫基)-4-氟-苯(1·〇 g)、碘化鉀(2〇 mg)及碳酸鉀(〇·7 g)之DMF(l〇 ml)混合物於l〇(TC加熱3小時,並放至隔夜冷 部至室溫。加入乙酸乙酯(5〇 mi)及水(25 ml)並以水沖洗有 機相,乾燥並真空濃縮。快速層析法(95:5 cH2Cl2:MeOH) 純化粗產物並於丙酮中與適量的稀HC1反應來製備其鹽酸 鹽,從乙醚中再結晶後得到丨·丨g(7〇%)白色結晶之純產 物。 lH NMR (400 MHz, DMSO): I.19 (3H, t)? 1.75 (2H5 br d)? 1.92-2.02 (2H,m),2·35 (2H,br q),2·59 (2H,q),2.92-3.09 (5H,m),3.10-3.20 (2H,m),3.47 (2H,br d),6·71-6·79 (1H, m),7.01(lH,dd),7.22(2H,brt),7.44-7.49 (2H,m),7.58-7.62 (1H,m),10.87 (1H,br s). 實例13 2-乙基-6-氟-3-{1-[3·(4-氟-苯基硫基)_丙基]_六氫σ比啶·‘ 基}-1_甲基-1Η-吲哚
於2-乙基-6-氣-3-{1-[3-(4-氟-苯基硫基)_两基]_六氯。比 咬-4-基卜1Η-吲哚(0.4 g)之DMF(5 ml)溶液中於5〇c加入氣 拌1 5分鐘。之後 並於室溫下將混 化鈉(0· 1 g)並將生成的混合物於室溫下搜 將混合物冷卻至5 C,加入Mel(0.1 ml), 97000.doc -36- 200526622 合物擾拌30分鐘。加入乙酸乙酯(50 ml)及水(50 ml),以水 冲洗有機層’以MgS〇4乾燥並真空濃縮。於丙g同中與適量 的稀HC1反應來製備其鹽酸鹽,從乙醚中再結晶後得到〇.2 g純產物(46%)之白色結晶。 lH NMR (400 MHz? DMSO): 1.12 (3H? t)5 1.74 (2H? br d)? 1.92-2.01(2H,m),2.29-2.42 (2H,m),2.78(2H,q),2.92-3.08 (5H,m),3·10-3·17 (2H,m),3·46 (2H,br d),3·62 (3H, s),6.79 (1H,br t),7.18-7.27 (3H,m),7.47 (2H,dd),7.66 (1H,dd)· 實例14-17 2-乙基-6-敗-3_{1-[3-(4-氟苯基硫基)-丙基]-1,2,3,6_四氫_。比 °定-4 -基} -1 -甲基-1Η - °引σ朵
咕 NMR (400 MHz,DMSO): 1·19 (3Η,t),1.19-2.10 (2Η, m),2.50-2.62 (1H,m),2.75-2.90 (3H,m),3·〇5 (2H,t), 3.31-3.39(3H,m),3.56-3.63 (lH,m),3.68(3H,s),3.70-3·81 (1H,m),3·93-4·02 (1H,m),5·62 (1H,br s),6·86 (1H, br t),7·22 (2H,t),7·29 (1H,dd),7.45-7.50 (3H,m). 2-乙基-5-氣-1-1-(3-對三氟甲基-本基-硫基-丙基)_六氫0比 97000.doc -37- 200526622 啶-4_基]-1Η-α引哚
咕 NMR (400 MHz,DMSO): 1.25 (3H,t),1.90 (2H,br d), 2.00-2.12 (2H,m),2.66-2.83 (4H,m),2.99-3.23 (6H,m), 3.51 (2H,br d),4.47-4.60 (1H,m),6.20 (1H,s),6·83 (1H, td),7.21 (1H,dd),7·54 (2H,dd),7.62-7.70 (3H,m)· 2_乙基-5-氣- l- {l-[3-(4 -氣-本基硫基)-3-甲基-丁基]-六鼠°比 啶-4-基}-111-吲哚
2 -乙基-5-氣-1-(1-{2-[1-(4 -氣-本基硫基)-壤丙基]-乙基}-六 氫吡啶-4-基)-1Η_吲哚
97000.doc -38- 200526622 實例18_20 2-乙基-6-氣- 3- [l-(3 -對二氣甲基-苯基-硫基-丙基)-六鼠σ比 啶-4-基]-1Η-吲哚
2-乙基-6-氟-3-{1-[3-(4-氟-苯基硫基)-3-甲基-丁基]•六氫口比 啶-4-基}-111-吲哚
2 -乙基-6-氣- 3- (1-{2-[1-(4 -氣-苯基硫基)-¾丙基]-乙基}-六 氮°比°定-4 -基)-1Η -叫| 11 朵
實例21-23 2-乙基-6-氣-1-甲基- 3- [1-(3-對二氣甲基-苯基-硫基-丙基)_ 97000.doc -39- 200526622
2 -乙基-6-氣- 3- {1-[3-(4 -氣-苯基硫基)-3 -甲基-丁基]-六氮°比 °定-4 _基} -1 -甲基-1Η - ^引ϋ朵
F
2 -乙基-6-氣- 3- (1-{2-[1-(4 -鼠-苯基硫基)-¾丙基]-乙基}-六 氫吡啶-4-基)-1-甲基-1H-吲哚
實例24-26 2-乙基-6-鼠- 3- [l-(3-對二氣甲基-苯基-硫基-丙基)-1,2,3,6_ 四鼠-口比口定-4 -基]-1Η -σ引口朵 97000.doc -40- 200526622
F
2-乙基-6-氣-3-{l-[3-(4-氣-苯基硫基)-3-甲基-丁基]- 1,2,3,6 -四氮-口比口定-4 -基} -1Η -σ引口朵
2 -乙基-6-氣- 3- (1-{2-[1-(4-氣-苯基硫基)-¾丙基]-乙基}-1,2,3,6 -四氮-0比σ定_ 4 -基)-1Η -σ引口朵
實例27-29 2-乙基-6-氣-1-甲基- 3- [1-(3-對二氣甲基-苯基-硫基-丙基)-1,2,3,6 -四氫-〇比咬-4-基]-1 H-口引σ朵 97000.doc -41 - 200526622
2-乙基-6-氣-3-{l-[3-(4-氣-苯基硫基)-3-甲基-丁基]-1,2,3,6-四氫^比啶-4-基}-1-甲基-1H_吲哚
2-乙基-6 -氣-3-(1_{2-[1-(4-氣-苯基硫基)-¾丙基]-乙基}-1,2,3,6-四氫-说啶-4-基)-1-甲基-111-吲哚
實例30-37 3-{3-[4-(2 -乙基-5 -氣-°引 ϋ朵-1 -基)-3,6 -二氮-2 Η - ^比 °定-1 -基]-丙基硫基}-[1,2,4]三唑并[4,3-a]。比啶 97000.doc -42- 200526622
F
4 NMR (400 MHz,DMSO): 1·22 (3H,t),1.63 (2H,br d), 1.73-1.83 (2H,m),1·98-2·11 (2H,m),2.19-2.34 (2H,m), 2·43 (2H,t),2·73 (2H,q),2·83 (2H,br d),3.15 (1H,t), 3.25-3.31 (1H,m),4.08-4.19 (1H,m),6.18 (1H,s),6.86 (1H,td),7.12 (1H,t),7.17 (1H,dd),7.37 (1H,dd),7.42 (1H,dd),7·82 (1H,d),8·48 (1H,d). 2-{3-[4-(2-乙基-5-氟-吲哚-1-基)_3,6-二氫-211-吡啶-1-基]-丙基硫基}-噻唑并[5,4-b]吡啶
F
4 NMR (400 MHz,DMSO): 1.25 (3H,t),1.75 (2H,br d), 1.97-2.08 (2H,m),2·20·2_33 (2H,m),2.41-2.51 (2H,m), 2.56-2.65 (2H,m),2.78 (2H,q),3.12 (2H,br d),3.49 (2H, t),4·18-4·30 (1H,m),6.20 (1H,s),6·87 (1H,td),7.19 (1H, dd),7.48-7.5 3 (2H,m),8.21 (1H,dd),8.50 (1H,dd)· 5 -氣- 2- {3-[4-(2 -乙基-5-氣-引11朵-1 -基)-六氮°比°定-1 -基]-丙 97000.doc -43- 200526622 基硫基}-苯弁ϋ塞哇
F
lR NMR (400 MHz, DMSO): 1.25 (3H? t)? 1.93 (2H, br d)? 2.30-2.42 (2H,m),2·81 (2H,q),2·99 (2H,br q),3.13-3.32 (4H,m),3.56 (2H,t),3.60-3.81 (2H,m),4.53-4.65 (1H,m), 6.22 (1H,m),6·82 (1H,br t),7·21 (1H,dd),7.43 (1H,dd), 7.91-8.02 (2H,m),8·08 (1H,dd). 2-{3-[4-(2 -乙基-5-氣-°弓丨 σ朵-1 -基)-3,6-二氣-2H-σ比 °定-1 -基]_ 丙基硫基卜苯并吟唑
F
{R NMR (400 MHz, DMSO): 1.27 (3H5 t)? 1.76 (2H? br d)5 1·99-2·09 (2H,m),2.19-2.27 (2H,m),2.40-2.53 (2H,m), 2.59 (2H,t),2.77 (2H,q),3·11 (2H,br d),3.43 (2H,t), 4.17-4.28 (1H,m),6.20 (1H,s),6·85 (1H,td),7.18-7.22 (2H,m),7·30-7·35 (2H, m),7·47-7·55 (1H,m),7.62-7.67 97000.doc -44 - 200526622 (1H,m). 2-乙基-5-氟-l-{l-[3-(5-三氟甲基比啶-2-基硫基)-丙基]-1,2,3,6 -四氫-。比 °定-4-基}- 1H-H 口朵
lH NMR (400 MHz? DMSO): 1.25 (3H? t)? 1.73 (2H? br d)5 1.73-1.82 (2H,m),2.12 (2H,br t),2.32-2.44 (3H,m),2.78 (2H,q),3.02 (2H,br d),3.24-3.32 (3H,m),4.13-4.23 (1H, m),6·20 (1H,s),6·85 (1H,td),7.20 (1H,dd),7.46-7.51 (1H,m),7.53 (1H,m),7.99 (1H,dd),8.81 (1H,s)· 2-乙基-6-氟-3-{l-[3-(4-氟苯基硫基)-丙基]六氫吼啶-3-基}-1//-吲哚
lU NMR (400 MHz, DMSO): 1.19 (3H? t)? 1.51-1.85 (6H? m),1.96 (1H,br· t),2.30-2.44 (3H, m),2.64-2.72 (3H,m), 2.83-2.90 (2H,m),2·93 (2H,t),6.70-6.78 (1H,m),6.99 (1H,dd),7·13 (2H,t),7.35-7.41 (2H,m),7.49-7.54 (1H, 97000.doc •45- 200526622 m),10.77 (1H,s). 3-{344-(2-乙基-5 -氟-吲嘴-1-基)-六氫°比唆-1-基]丙基硫 基}-苯甲酸乙酯
F
熔點 179-1 81 °C · 3-{3-[4-(2-乙基-5-氣-°引ϋ朵-1-基)-六氮^比淀-丨-基]丙基硫 基卜苯甲酸 〇
A NMR (400 MHz,DMSO): 1.25 (3Η,〇, 1·90 (2Η,br. d), 198-2.10 (2H,m),2.72-2.88 (4H,m),3.02-3.21 (7H,m), 3·44-3·60 (2H,m),4·53 (1H,br· s),6.21 (1H,s),6.88 (1H, td),7·22 (1H,dd),7·49 (1H,t),7.68 (1H,br. d),7.70-7.80 (2H,m)5 7.88 (1H,s). 治療方法 火因此,本發明係關於可有效用於預防及/或治療各毛 火性、感染性及免疫調節症狀或疾病之化合物,該“ 97000.doc -46- 200526622 疾病包括氣喘及過敏抖 ^ 7 、 生疾病、病理性微生物感染(依定 義’包括病毒)’以及白鱗 自體免疫病理例如類風濕關節炎及 動脈硬化。 例如’投予可抑制_或多種哺乳動物趨化激素受體(例 如人闕化激素叉體)之本發明化合物以抑制(亦即降低或 預防)發炎性或感染性疾病。因Λ,一或多種發炎過程例 如白血球遷移、黏附、趨化性、胞泌作用(例如酵素、級 、哉胺的刀泌)或發炎性中間物的釋放,即受到抑制。例如 發炎部位之嗜伊紅Α球浸潤(如於氣喘或過敏性鼻炎)可祀 據本方法來抑制。特而言之,在上述分析中,❹適當趨 化激素,則下列實例之化合物具有PiL斷表現ccr 胞之遷移的活性。 ''' 同樣的可增進一或多種哺乳動物趨化激素受體(例如 人類趨化激素受體)功能之本發明化合物,當投予用以刺 激(引,或增進)免疫或發炎反應,(例如白血球遷移、黏 附、趨化性、胞泌作用(例如酵素、組織胺的分泌)或發^ 性中間物的釋放,產生有利的發炎過程刺激。例如可= 嗜伊紅血球對抗寄生蟲的感染。此外,若經由趨化激:: 體内在化作用的誘導將足量的化合物送入而造成表現在細 胞上受體流失,或將化合物以可導致細胞遷移方向錯誤之 方式达人’則治療前述的發炎性、過敏性及自體免疫性疾 病亦可視為—種本發明化合物其增進-或種哺乳動物之趨 化激素受體之功能。 除了靈長類(例如人類)外’其他各類的哺乳動物亦可根 97000.doc -47· 200526622 據本發明方法來治療。例如,亦可治療哺乳動物包括(但 不限於)乳牛、綿羊、山羊、馬、狗、猫、天竺鼠、老鼠 及其他钱、綿羊、馬類、犬科、猶科1齒科或海中物 種n該方法亦可施行於其他物種,例如禽類動物。 以上述方法治療之對象係為雄性或雌性的哺乳動物,係希 望可調節其趨化激素受體之活性。本文所用的「調節」係 希望包含拮抗作用、激動作用、部分拮抗作用及/或部分 激動作用。 可以趨化激素受體功能抑制劑治療之人類或其他物種之 疾病或症狀包括(但不限於)發炎或過敏性疾病,包括呼吸 過敏疾病例如氣喘、過敏性肺部疾病、過敏性肺炎、嗜伊 紅性蜂窩組織炎(例如威爾氏徵候群(Well,s syndr〇me))、 嗜伊紅性肺炎(例如呂弗勒氏肺炎(Loeffler,s syndr〇me)、 k性嗜伊紅性肺炎)、嗜伊紅性肌膜炎(例如舒爾曼徵候群 (Shulmanis syndr〇me))、遲發性過敏反應、間質性肺病 (ILD)(例如特發性肺纖維化、或與類風濕關節炎有關之 ILD、全身性紅斑狼瘡、僵直性脊椎炎、全身性硬化症、 修格連氏徵候群或皮肌炎)、全身性過敏反應或過敏反 應、藥物過敏(例如對盤尼西林或頭孢菌素 (Cephal〇Sporins)過敏)、因攝入受污染的色胺酸所引起的 嗜伊紅血球增多性肌肉痛徵候群、昆蟲叮咬過敏、自動免 疫性疾病例如類風濕關節炎、乾癬性關節炎、多發性硬化 症、全身性紅斑狼瘡、重症肌無力、青少年糖尿病、腎小 球月尺、自體免疫性甲狀腺炎、貝氏症、移植排斥(例如 97000.doc -48 * 200526622 移植)包括異體移植物的排斥或移植物抗宿主症、發炎性 肪道疾病例如克隆氏症(Crohn’s disease)及潰瘍性結腸炎、 脊椎關節病變、硬皮病、牛皮癬(包括τ細胞所介導的牛皮 癣)及發炎性皮膚病例如皮膚炎、濕疹、異位性皮膚炎、 過敏型接觸性皮膚炎、蓴麻疹、血管炎(例如壞死性、皮 膚性及過敏性血管炎)、嗜伊紅性肌炎、嗜伊紅性肌膜 炎、與皮膚或器官之白血球浸潤有關之癌症。可抑制不欲 的电k反應來治療之疾病或症狀包括(但不限於)再灌注損 傷、動脈硬化、某些血液惡性腫瘤、細胞激素誘發之毒性 (例如敗血性休克、内毒素性休克)、多發性肌炎、皮肌 炎。可以趨化激素受體功能抑制劑治療之人類或其他物種 之感染性疾病或症狀包括(但不限於)Hiv。 可以趨化激素受體功能促進劑治療之人類或其他物種之 疾病或症狀包括(但不限於)抑制免疫,例如個體之免疫缺 乏徵候群如AIDS或其他病毒感染,接受會引起抑制免疫 之放射線治療、化學治療、自體免疫疾病之治療或藥物治 療(例如類固醇治療)之個人;先天性受體功能障礙或其他 因素所引起的抑制免疫;及感染性疾病,例如寄生蟲病其 包括(但不限於)蠕蟲感染疾病,例如線蟲(蛔蟲);(鞭蟲病 (Trichuriasis)、蟯蟲病(Enterobiasis)、蛔蟲病 (Ascariasis)、鈎蟲病(Hookworm)、桿線蟲症 (Strongyloidiasis)、旋毛蟲病(Trichin〇sis)、絲蟲病 (filariasis));吸蟲病(trematodes)(吸蟲(flukes))(肝吸蟲病 (Schistosomiasis)、肺吸蟲病(Clonorchiasis))、絛蟲 97000.doc -49- 200526622 (cestodes)(絛蟲(tape worms))(胞蟲症(Echinococcosis)、牛 肉絛蟲(Taeniasis saginata)、囊蟲病(Cysticercosis))、内臟 寄生蟲、内臟性幼蟲移行症(visceral larva migraines)(例如 弓漿蟲(Toxocaira))、嗜伊紅血球性胃腸炎(例如Anisaki 屬、復管線蟲屬(Phocanema sp))、皮膚幼蟲移行症 (cutaneous larva migraines)(巴西鉤蟲(AnCy1〇st〇na braziliense)、犬鉤蟲(Ancylostoma caninum))。本發明化合 物因此可有效用於預防和治療各種發炎性、感染性及免疫 凋節性障礙和疾病。此外,若經由趨化激素受體内在化作 用的誘‘,投遞足量的化合物而造成表現在細胞上受體喪 失,或化合物之投遞係以導致細胞遷移方向錯誤之方式, 則前述之發炎性、過敏性及自體免疫性疾病之治療亦可視 為趨化激素受體功能促進劑。 一在另一方面,本發明可用於評估推定之特定G蛋白偶^ 又體激動劑或拮抗劑。本發明係關於該等化合物用於製伟 及執行篩選具調節趨化激素受體活性之化合物之用途。'^ :’本發明化合物可有效用於確定及測定其他化合物盘超 激素的結合位置,例㈣錢爭㈣抑制作 展新:::::::化:與已知活性之化合物比較。二 用。 $方法中,根據本發明化合物可用於檢驗其效 例如用於 可有效用 利用本發 s特別的’ 3亥等化合物可以商業套組方式提, :前述疾病有關之醫藥研究上。本發明化〜 評估推定特定之趨化激素受體調節劑。此; 97000.doc •50- 200526622 明化合物作為不會與其結合之實例化合物,或作為可幫助 找出交互作⑽定位置之活化於該等受體之化合物結構變 體,則本發明化合物可用來檢驗不被認為是趨化激素受體 之G蛋白偶合觉體的專一性。 醫藥形式 式1化合物係以治療有效量投予哺乳動物。「治療有效 Ϊ」係指當單獨或與其他治療劑組合投與時,式i化合物 的里可有效預防或改善疾病或該疾病的惡化,其中該疾病 係與CCR-3受體之活性有關。 本發明化合物可以口服劑型的方式投藥,例如旋劑、膠 囊(包括持續釋放或定時釋放之調配物)、丸劑、散劑、粒 劑、酿劑、自丁劑、懸浮劑、糖襞及乳劑。其亦可以靜脈内 (推注或輸液劑)、腹腔内'皮下或肌肉内形式給藥,所有 使用的劑型係為熟f本項技藝者所熟知。其可單獨投予, 但通常:與—醫藥載劑-起投予’而該醫藥載劑係依所選 擇的投藥路徑及標準醫藥實行為基準所選出。 一本發明化合物之劑量療法,當然係依各種已知的因素而 定’例如特;t藥劑之藥物動力學特性及投予的模式和路 徑、接受者的物種、年齡、性別、健康、醫療狀況及體 重症狀本身及持續性、協同治療種類、治療頻率、投藥 路徑、病患之腎臟及肝功能和所欲的效果。醫師或獸醫師 可决疋亚開立預防疾病、對抗疾病或阻止疾病惡化 有效藥量。 經由通用指南 用於指定效果之每種活性成份之每日口 97000.doc -51 - 200526622 服劑里,係介於約0.001至1000 mg/kg體重 A固間,輕传 的係介於每天約0.01至1〇〇 mg/kg體重 取1土的係介於 1.0至20 mg/kg/天。靜脈給藥最佳的劑量係 、 ^、約1至約1 〇 mg/kg/分鐘之固定流速的輸液。本發明化合物可以a 一劑型投予,或將每日總劑量分成每日二、單 —或四次投 本發明化合物可以鼻内形式經由適合鼻内媒劑之局部心 藥,或經由皮膚穿透路徑,使用穿透皮膚貼布給藥。當= 穿透皮膚遞送系統之形式給藥時,投予的劑量當然為 的,而整個劑量療程不能中斷。 % 典型的,式1化合物係與適合的醫藥稀釋劑、賦形劑或 載劑(整體而言,本文喜好以醫藥載劑表示)混合投予,令 醫藥稀釋劑、賦形劑或載劑係適當的選自符合所欲投藥= 式如口服錠劑、膠囊、酏劑、糖漿及其類似物,並符合習 用的醫藥實行。 σ 例如,以口服投藥之旋劑或膠囊而言,活性藥物組份可 與口服、無毒性、醫藥上可接受、惰性載劑組合,例如乳 糖、澱粉、嚴糖、葡萄糖、甲基纖維素、硬脂酸鎮、磷酸 氫舞、硫酸約、甘露醇、山梨糖醇及其類似物;以液體形 式口服投藥而言,口服活性藥物組份可與任何口服、無毒 性、醫藥上可接受的惰性載劑組合,例如乙醇、甘油、2 及其類似物。再者,當希望或必須時,適合的結著劑、潤 滑劑、分裂劑及著色劑亦可併入混合物中。適合的結著劑 包括澱粉、明膠、天然糖類如葡萄糖或化乳糖、玉米甜: 97000.doc •52- 200526622 劑、天然及合成膠自如阿拉伯膠、黃蓍膠或海藻酸鈉、羧 曱基纖維素、聚乙二醇、蠟及其類似物。用於這些劑型之 >閏滑劑包括油k納、硬脂酸納、硬脂酸錢、苯甲酸鈉、醋 酸鈉、氯化鈉及其類似物。分裂劑包括(但不限於)澱粉、 曱基纖維素、糖、膨潤土(bentonite)、三仙膠(xanthan gum)及其類似物。 本發明化合物亦可以脂質體遞送形式來投藥,例 如小微脂粒、大微脂粒、多層微脂粒。脂質體可由 各種鱗脂吳形成’例如膽固醇、硬脂胺或卵鱗脂 (phosphatidylcholines) ° 本發化合物亦可與作為標的藥物載體之適合的聚合物偶 合。該等聚合物可包括聚乙烯吡咯啶酮,吡喃共聚物、聚 羥基丙基甲基丙烯醯胺-酚,聚羥基乙基天門冬醯胺酚或 經棕櫚醯基殘基取代之聚環氧乙烷聚離胺基酸。 再者,本發明化合物亦可與一種可有效控制藥物釋放之 可生物降解聚合物偶合,例如聚乳酸、聚乙醇酸、聚乳酸 及聚乙醇酸之共聚物、聚己内酯(p_epsil〇n CaPn)lactone)、聚羥基丁酸、聚原酸酯、聚酸醛、聚二氫 比南來氰丙烯酸酯及交鏈或兩性異量分子聚合物 (amphipathic block copolymers)凝膠。 適合投藥之劑型(醫藥組合物)每劑量單位可含有約1毫 克至約100毫克的活性成份。 在這二w藥組合物中,活性成份一般係以約組合物總重 i之0.5-95%重量比的量存在。 97000.doc -53- 200526622 明膠膠囊可含有活性成份及散劑載體, =、纖維素衍生物、硬脂酸鎂、硬㈣及其_物;; 的稀釋劑亦可包含於㈣,lt。錠劑和膠囊兩 、 釋放產物方式來製逆,以接征幽,± 符,.貝 飞术衣&,以如供幾小時期間内持續釋放之藥 物治療。虔製的錠劑可包上糖衣或臈衣以掩飾任何不良的 味道並保護㈣!免受空氣侵害,《包上可於腸胃道令選擇 性分解之腸衣。 口服投藥之液體劑型可含有調色及調味劑以增加病患的 接受度。 二般而言,水、適合的油脂、食鹽水、右旋糖水溶液 (葡萄糖)及相關的糖溶液及甘油醇例如乙二醇或聚乙二醇 皆為適合的腸外溶液之載劑。腸外投藥之溶液較佳的係含 有/舌丨生成伤之水溶性鹽類、安定劑,若需要可含有緩衝 物質。抗氧化劑例如亞硫酸氫鈉、亞硫酸鈉或抗壞血酸 (單獨或組合)皆為適合的安定劑。亦可使用檸檬酸及其鹽 類和EDTA納。此外,腸外溶液可含有防腐劑例如苯甲烷 氣化銨(benzalkonium chloride)、羥基笨甲酸甲酯或丙酯及 氯丁醇。 描述適合的醫藥載劑之Mack出版公司之Reminqton,s Pharmaceutical Sciences係為本領域標準的參考文獻。 當二或多種前述之第二治療劑與式1化合物共同投予 時,相對於當單獨投予時之一般藥劑的劑量,通常,典型 的可降低每日劑量及每日劑型之每種組份的量,當組合投 藥時,需考慮治療藥劑之附加及協同效用。 97000.doc -54- 200526622 特而言之,當提供單一劑量單位時,在組合的活性成份 間存在有潛在的化學交互你田 予又互作用。因此,當式1化合物及第 ^台«劑組合成單-劑量時,雖然活性成份係組合於〆 早一劑Ϊ早位中,但可以減少(亦即降低)活性物質間的物 理性接觸之方式來調配。例如,纟中一個活性成份可包覆 腸衣#由膠其中種成份包覆腸衣,盡可能的不只降低 組合的活性成份之接觸,亦可控制其中_種組份在腸胃道 中的釋放’而使知其中一種組份不是在胃中的釋放,而是 在腸内釋放。其中-種組份亦可包覆上—種可在整個腸胃 到中持_釋放之物質,並亦可減少組合的活性成份間之物 理性接觸。 再者’持續釋放組份可額外包覆腸衣,使該組份只能在 腸中釋放。而另一方面係關於組合產物之調配,其中一種 組伤係包覆一種持續或腸中釋放之聚合物,而另一種組份 亦包覆上一種低黏度之羥丙基甲基纖維素(HPMC)之聚合 物’或其他本項技藝中已知之適合的物質,以更進一步將 活性組份分開。該聚合物膜衣係可形成組合的活性物質成 份間之額外的屏障。 熟習本項技藝者應了解,本揭示文中所揭示的,這些及 其他減少本發明組合產物之組份間接觸之方法,無論以單 一劑型投藥或以分開形式投藥,但係以同樣的方式在相同 時間投予。 97000.doc -55-
Claims (1)
- 200526622 十、申請專利範圍: 1. 一種式1化合物, R1其中 Rl 為芳基、het或其增環部分(annelated species),其中het為一雜環而增環部分係包 括芳基-het_、het-芳基-或het-het-增環,每一 個該芳基或可經一、二或三個R2取代; r2 各自分別為Ci-6-烷基、c3-6-環烷基、Cl_6-鹵 烧基、ci-6-芳烷基、鹵素、CN、COOR3、 COR3、c〇NR3R4、NR3R4、nr3so2r4、 〇R3、N02、SR3、S〇R3、s〇2R3 或 so2nr3r4 ; R 為H Ci-6-院基、C3_8-環烧基或(c3_8•環燒 基)-C w烷基; R4 為H,Cy烷基、C3-8-環烷基或(c3 8·環烷 基)-C w烷基或 R3及R4 與居間的氮原子或N-S〇2-基團共同形成一個 可視需要經取代之含有3至8個成員的氮雜環 R 為Cl-6·烷基、CN6-烷氧基、CN6-醯氧基、 Gw-芳烷基、c3_6_環烷基、(C3 6_環烷 97000.doc 200526622 基)-Ci_6 -烧基、Ci_6-鹵烧基、Ci_6 -硫烧基、 鹵素、N〇2、CN ; R6 各自分別為-烷基 、Ci_6_ 烷氧基、 C 1_6_ 驢 氧基、 c 1 -6" 芳烷基、C3_6-環烷基、C 1_6-鹵烧 基、Cb6-硫烷基、鹵素、OR3、SR3、CN、 N02、COOR3、COR3、CONR3R4、NR3R4、 NR3COR4、NR3S02R4、SOR3、S02R3、 S02NR3R4、芳基或het ; A 為(C3_6環烷基)-C2_8-伸烷基、直鏈或支鏈 c2_8-伸烷基、視需要經鹵素或OH取代; B 為芳基或het ; D-E 為 CH-CH2-或 C=CH- X-W-V 為 N-OCR7或 C=C-NR7 ; R7 為H*CN6-烷基; Y 為 CF2、NR4、Ο、S(0)n ; i、j 各自分別為〇、1或2,其中0 S i+j S 4 ; η 為0、1或2 ; m 為0、1、2、3或 4; 及其醫藥上可接受之鹽類。 2. —種式la之化合物,97000.doc -2 - 200526622 及R、R5、R6、A、B、D-E、X-W-V、i、 項1之定義。 3 · —種式1 b之化合物, j及m係如請求 b ί ίΕΎ\ν,s、a-n、^ R5 lb 及 Ri、R5、 項1之定義。 4·根據請求項1-3中任一項之化合物,其中 R為 芳基或het,兩者皆可視需要經 R2取代及 6為 苯基。 5 ·根據睛求項1 -3中任一項之化合物,其中 : 本基’視需要可經一、二或三個R取代 6·根據凊求項丨_3中任一項之化合物,其中 A、B、D-E、X-W-V j及m係如請求 二或三個 D-E為 CH-CH' 根據請求項1-3中任-項之化合物,其中 A為 CH2-CH2-CH2- 0 8·根據請求項1-3中任一項之化合物,其中 A為 C(CH3)2-CH2-CH2- 9 · 根據清來Ί。. ^項1 -3中任一項之化合物 A為 其中 -,C、-CH2-CHf C一 C h2h2 97000.doc 200526622 1 〇·根據明求項1 -3中任一項之化合物,其中 R為 烷基、c3_6-環烷基、C2_6-鹵烷基。U·根據請求項1-3中任一項之化合物,其中 X-W-V為 n-C = CR7。 12·根據睛求項1-3中任一項之化合物,其中 R1為 苯基,視需要可經一、二或三個R1取代及 R2 各自分別為 COOR2 、 COR2 、 CONR2R4 、 R2為 R4為 NR2S02R4、SOR2、so2r2或 S02NR2R4 ; H或烧基; H或C烧基。 13· 一種製備根據請求項卜2中任一項之式1、la或lb之化合 物’其特徵為將式2之化合物 ΗR13 其中 R1、R5、R6、A、Β、D-E、x w ν . · u 乂 t X-W-V、l、j 及 m係 3 求項1之定義及 適合的游離基’係選自齒素、甲石黃酸鹽、三專 基h酸鹽、甲苯磺酸鹽或對溴笨磺酸鹽。 97000.doc 1 2 與式3之化合物反應, 200526622 14. 15. 16. 17. 一種醫筚έθ w 據請求項U3 、 孑夕種根 任項之式1、1 a或1 b之化合物。 根據請求項 中任一項之式1、la或lb之化合物,甘〆 作為醫藥品。 初其係 根據請求頂1 1 、 中任一項之式1、la或lb之化合物因 備供預防或、Λ :製 乂口療其中CCR3活性調節劑具有治療利χ 病之醫藥品之用途。 j皿之疾 只,用於治療或預防其中ccr3活性調節劑係'具有治療利 兮旦;、;丙之酉藥組合物’其包括-種治療上或預防上有 ^之根據請求们_3中任—項之式之化合 物0 97000.doc 200526622 七、指定代表圖: (一) 本案指定代表圖為:(無) (二) 本代表圖之元件符號簡單說明: 八、本案若有化學式時,請揭示最能顯示發明特徵的化學式:97000.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03026170 | 2003-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200526622A true TW200526622A (en) | 2005-08-16 |
Family
ID=34610050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093135011A TW200526622A (en) | 2003-11-17 | 2004-11-16 | Novel piperidine-substituted indoles- or heteroderivatives thereof |
Country Status (19)
Country | Link |
---|---|
US (1) | US7544806B2 (zh) |
EP (1) | EP1687294B1 (zh) |
JP (1) | JP4825679B2 (zh) |
KR (1) | KR20060127000A (zh) |
CN (1) | CN1882565A (zh) |
AR (1) | AR047123A1 (zh) |
AU (1) | AU2004291297B2 (zh) |
BR (1) | BRPI0416665A (zh) |
CA (1) | CA2545261C (zh) |
IL (1) | IL175678A (zh) |
MX (1) | MXPA06004626A (zh) |
MY (1) | MY143862A (zh) |
NZ (1) | NZ547314A (zh) |
PE (1) | PE20051007A1 (zh) |
RU (1) | RU2382037C2 (zh) |
TW (1) | TW200526622A (zh) |
UY (1) | UY28618A1 (zh) |
WO (1) | WO2005049559A2 (zh) |
ZA (1) | ZA200601800B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7759365B2 (en) | 2005-04-30 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Piperidine-substituted indoles |
ATE524461T1 (de) * | 2006-10-27 | 2011-09-15 | Boehringer Ingelheim Int | Neue substituierte piperidylpropanthiole |
CA2667547C (en) * | 2006-10-27 | 2014-07-29 | Boehringer Ingelheim International Gmbh | Piperidyl-propane-thiol ccr3 modulators |
WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2533924A1 (fr) * | 1982-10-05 | 1984-04-06 | Roussel Uclaf | Nouveaux derives du 4-(1h-indol-3-yl)a-methyl piperidine-1-ethanol, leurs sels, le procede de preparation, l'application a titre de medicaments et les compositions les renfermant |
US5521197A (en) | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
US5576321A (en) * | 1995-01-17 | 1996-11-19 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
CA2259927A1 (en) * | 1996-07-12 | 1998-01-22 | Leukosite, Inc. | Chemokine receptor antagonists and methods of use therefor |
US5962473A (en) | 1996-08-16 | 1999-10-05 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F |
AU4074897A (en) | 1996-09-18 | 1998-04-14 | Eli Lilly And Company | A method for the prevention of migraine |
AR013669A1 (es) * | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
CA2319198C (en) * | 1998-01-27 | 2011-02-22 | Aventis Pharmaceuticals Products Inc. | Substituted oxoazaheterocyclyl factor xa inhibitors |
ES2165274B1 (es) * | 1999-06-04 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos. |
CA2394548A1 (en) | 1999-12-17 | 2001-06-21 | Joseph P. Yevich | Antipsychotic heterocycle compounds |
AU3231901A (en) * | 2000-02-18 | 2001-08-27 | Meiji Seika Kaisha | Phenoxyalkylamine derivatives useful as opioid delta receptor agonists |
TR200401488T4 (tr) | 2000-07-21 | 2004-08-23 | H. Lundbeck A/S | CNS bozukluklarının tedavisinde faydalı indol türevleri |
ES2201899B1 (es) * | 2002-04-01 | 2005-06-01 | Almirall Prodesfarma, S.A. | Derivados de la azaindolilpiperidina como agentes antihistaminicos y antialergicos. |
US7157471B2 (en) * | 2003-08-25 | 2007-01-02 | Boehringer Ingelheim International Gmbh | Haloalkyl- and piperidine-substituted benzimidazole-derivatives |
US7759365B2 (en) * | 2005-04-30 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Piperidine-substituted indoles |
-
2004
- 2004-11-11 RU RU2006121328/04A patent/RU2382037C2/ru not_active IP Right Cessation
- 2004-11-11 WO PCT/EP2004/012775 patent/WO2005049559A2/en active Application Filing
- 2004-11-11 AU AU2004291297A patent/AU2004291297B2/en not_active Ceased
- 2004-11-11 CA CA2545261A patent/CA2545261C/en not_active Expired - Fee Related
- 2004-11-11 KR KR1020067012008A patent/KR20060127000A/ko active IP Right Grant
- 2004-11-11 MX MXPA06004626A patent/MXPA06004626A/es active IP Right Grant
- 2004-11-11 JP JP2006538792A patent/JP4825679B2/ja not_active Expired - Fee Related
- 2004-11-11 NZ NZ547314A patent/NZ547314A/xx not_active IP Right Cessation
- 2004-11-11 CN CNA2004800338440A patent/CN1882565A/zh active Pending
- 2004-11-11 EP EP04818773.6A patent/EP1687294B1/en not_active Not-in-force
- 2004-11-11 BR BRPI0416665-5A patent/BRPI0416665A/pt not_active IP Right Cessation
- 2004-11-12 MY MYPI20044731A patent/MY143862A/en unknown
- 2004-11-15 PE PE2004001117A patent/PE20051007A1/es not_active Application Discontinuation
- 2004-11-15 UY UY28618A patent/UY28618A1/es not_active Application Discontinuation
- 2004-11-16 US US10/990,059 patent/US7544806B2/en active Active
- 2004-11-16 TW TW093135011A patent/TW200526622A/zh unknown
- 2004-11-17 AR ARP040104231A patent/AR047123A1/es not_active Application Discontinuation
-
2006
- 2006-03-02 ZA ZA200601800A patent/ZA200601800B/en unknown
- 2006-05-16 IL IL175678A patent/IL175678A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NZ547314A (en) | 2010-02-26 |
EP1687294B1 (en) | 2014-05-21 |
JP2007511480A (ja) | 2007-05-10 |
AU2004291297A1 (en) | 2005-06-02 |
US7544806B2 (en) | 2009-06-09 |
AU2004291297B2 (en) | 2011-06-23 |
WO2005049559A3 (en) | 2006-04-13 |
CA2545261A1 (en) | 2005-06-02 |
CA2545261C (en) | 2013-07-23 |
UY28618A1 (es) | 2005-06-30 |
WO2005049559A2 (en) | 2005-06-02 |
AR047123A1 (es) | 2006-01-11 |
KR20060127000A (ko) | 2006-12-11 |
US20050153979A1 (en) | 2005-07-14 |
IL175678A (en) | 2012-08-30 |
ZA200601800B (en) | 2007-05-30 |
CN1882565A (zh) | 2006-12-20 |
MXPA06004626A (es) | 2006-06-27 |
RU2382037C2 (ru) | 2010-02-20 |
BRPI0416665A (pt) | 2007-01-16 |
IL175678A0 (en) | 2006-09-05 |
MY143862A (en) | 2011-07-15 |
JP4825679B2 (ja) | 2011-11-30 |
RU2006121328A (ru) | 2008-01-10 |
PE20051007A1 (es) | 2005-12-26 |
EP1687294A2 (en) | 2006-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102031846B1 (ko) | Ccr(4) 길항제로서의 치환된 벤즈이미다졸 및 벤조피라졸 | |
CN105960237B (zh) | Ccr6化合物 | |
CA2888480C (en) | Heteroaryl linked quinolinyl modulators of ror.gamma.t | |
CA2888485A1 (en) | Phenyl linked quinolinyl modulators of ror.gamma.t | |
HU229709B1 (en) | Piperazinyilpiperidine derivatives as chemokine receptor antagonists | |
JP2005506330A (ja) | ケモカイン(特にccr3)活性のモジュレーターとしてのピペリジン誘導体およびその使用 | |
US20060030590A1 (en) | Alkyl-and piperidine-substituted benzimidazole derivatives | |
IL175678A (en) | Piperidine-substituted indoles or heteroderivatives thereof, process for their preparation and pharmaceutical compositions comprising them | |
CA2926313A1 (en) | Secondary alcohol quinolinyl modulators of roryt | |
JP4783286B2 (ja) | ハロアルキル置換及びピペリジン置換ベンゾイミダゾール誘導体 | |
TW200409630A (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
US7157471B2 (en) | Haloalkyl- and piperidine-substituted benzimidazole-derivatives | |
JPH10130240A (ja) | Icam−1産生阻害剤 | |
JP2009513517A (ja) | N−(ヘテロビシクロアルカン)−置換インドール又はそのヘテロ誘導体 |